Study of acute toxicity of new thiophene-containing derivatives of 1,2,4-triazole
DOI:
https://doi.org/10.14739/2310-1210.2023.1.266318Keywords:
acute toxicity, rats, 1,2,4-triazole derivativesAbstract
Acute toxicity studies are an integral part of preclinical studies of any new biologically active compound. It should be noted that it is this stage of research that is crucial regarding the possibility of further use of a pharmacologically active substance as a drug. This indicator also helps to determine the initial dose for clinical trials and establish a range of potentially safe doses. The data obtained will help determine the direction of new chemical syntheses, replenish the relevant libraries in silico, as well as reveal many other fundamentally important parameters that characterize the interaction in the compound – living organism system.
The aim of this research is to study the acute toxicity of 2-((4-phenyl-5-(thiophene-3-ylmethyl)-1,2,4-triazole-3-yl)thio)sodium acetate.
Materials and methods. Previously, a prediction was made using the GUSAR computer program, which helped determine the dose intervals. Acute toxicity was determined by the experimental method of Kerber in vivo using white nonlinear Wistar rats. The rats were weighed, labeled, and divided into five groups of six individuals of each.
Results. After the introduction of compound moving activity decreased, drowsiness, pupil miosis, and thirst were observed. In the fifth group, with the maximum dilution, all rats died within two hours after administration of the test compound. During the death, convulsions were observed. In the fourth group five animals died, and in the third – two rats died. In the first two groups, all the rats survived. During follow-up, the animals behaved normally. Based on the results of the research, calculations were made and the LD50 indicator was determined.
Conclusions. According to the results, the studied compound belonged to the V class of toxicity (almost non-toxic), and the resulting LD50 value was 1125 mg/kg. This indicator confirmed the prospects for further study of this compound.
References
Liu, Z., Dang, K., Gao, J., Fan, P., Li, C., Wang, H., Li, H., Deng, X., Gao, Y., & Qian, A. (2022). Toxicity prediction of 1,2,4-triazoles compounds by QSTR and interspecies QSTTR models. Ecotoxicology and environmental safety, 242, 113839. https://doi.org/10.1016/j.ecoenv.2022.113839
Opsomer, T., & Dehaen, W. (2022). 1,2,4-Triazoles. In Comprehensive Heterocyclic Chemistry IV (pp. 78-121). Elsevier. https://doi.org/10.1016/b978-0-12-409547-2.14854-1
Shcherbyna, R. O., Danilchenko, D. M., Parchenko, V. V., Panasenko, O. I., Knysh, E. H., Hromyh, N. A., & Lyholat, Y. V. (2017). Studying Of 2-((5-R-4-R-1-4H-1,2,4-Triazole-3-Yl)Thio)Acetic Acid Salts Influence On Growth And Progress Of Blackberries (KIOWA Variety) Propagules. Research Journal of Pharmaceutical Biological and Chemical Sciences, 8(3), 975-979.
Kaplaushenko, A. H., Parchenko, V. V., Panasenko, O. I., Knysh, Ye. H., & Darii, K. V. (2008). Syntez i hostra toksychnist solei 2-[(5-R-4-R1-1,2,4-triazol-3-iltio)-2-(karboksymetyltio)karbonotioil] hidrazynoatsetatnykh kyslot [Synthesis and acute toxicity of salts of 2-[(5-R-4-R1-1,2,4-triazole-3-ylthio)-2-(carboxymethylthio)-carbonothioyl]hydrazinoacetate acids]. Current issues of pharmaceutical and medical science and practice, 21, (Vol. 2, pp. 87-92). [in Ukrainian].
Bigdan, O. (2021). Toxicity of Substance BKP-115 on Rats and Mice of Both Sexes at Long Term Intragastric Introduction. Archives of Pharmacy Practice, 12(2), 6-11. https://doi.org/10.51847/v8mvj5iqgt
Bielenichev, I. F., Vizir, V. A., Mamchur, V. Yo., & Kuriata, O. V. (2019). Mesto tiotriazolina v galeree sovremennykh metabolitotropnykh lekarstvennykh sredstv [Place of tiotriazoline in the gallery of modern metabolitotropic medicines]. Zaporozhye medical journal, 21(1), 119-128. [in Russian]. https://doi.org/10.14739/2310-1210.2019.1.155856
Belenichev, I., Kucherenko, L., Pavlov, S., Bukhtiyarova, N., Popazova, O., Derevianko, N., & Nimenko, G. (2022). Therapy of post-COVID-19 syndrome: improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (thiotriazoline). Pharmacia, 69(2), 509-516. https://doi.org/10.3897/pharmacia.69.e82596
Belenichev, I., Kucherenko, L., Nagornaya, E., Mazur, I., Bidnenko, A., Bukhtiyarova, N., & Avramenko, N. (2015). Functional nitric oxide conjugate systems state/restored heart thiols of rats in modeling isadrine-pituitrin’s myocardial infarction using metabolite-tropic cardioprotector “Angiolin”. International Journal of Basic & Clinical Pharmacology, 4(1), 15-21. https://doi.org/10.5455/2319-2003.ijbcp20150238
Belenichev, I. F., Aliyeva, E. G., Kamyshny, O. M., Bukhtiyarova, N. V., Ryzhenko, V. P., & Gorchakova, N. O. (2022). Pharmacological Modulation of Endogenous Neuroprotection after Experimental Prenatal Hypoxia. Neurochemical Journal, 16(1), 68-75. https://doi.org/10.1134/s1819712422010044
(1999). Direktiva Soveta ES o sblizhenii zakonov, postanovlenii i administrirovanie polozhenii gosudarstv ES po voprosam zashchity zhivotnykh, ispol'zuemykh dlya eksperimental'nykh i drugikh nauchnykh tselei (86/609/EES) [Directive of the Council of the EU on the convergence of laws, decrees and administrations of the EU states on the protection of animals used for experimental and other scientific purposes (86/609/EEC)]. In N. A. Lyapunov, V. A. Zagorii, V. P. Georgievskii, & E. P. Bezuglaya (Eds.), Nadlezhashchaya proizvodstvennaya praktika lekarstvennykh sredstv [Appropriate production practice of medicinal products] (pp. 508-545). Morion. [in Russian].
Stefanov, O. V. (Ed.). (2001). Doklinichni doslidzhennia likarskykh zasobiv [Preclinical studies of medicinal products: methodical recommendations]. Kyiv: Avicena. [in Ukrainian].
Bak, P. G., Belenichev, I. F., Kucherenko, L. I., Abramov, A. V., & Khromylova, O. V. (2021). Morpho-functional indicators changes of rats’ myocardium in experimental doxorubicin-induced chronic heart failure and its pharmacological modulation with new 4-amino-1,2,4-triazole derivative. Pharmacia, 68(4), 919-925. https://doi.org/10.3897/pharmacia.68.e75298
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
